Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Enhancing nicotine vaccine immunogenicity with liposomes.

Lockner JW, Ho SO, McCague KC, Chiang SM, Do TQ, Fujii G, Janda KD.

Bioorg Med Chem Lett. 2013 Feb 15;23(4):975-8. doi: 10.1016/j.bmcl.2012.12.048. Epub 2012 Dec 27.

2.

A novel and efficient nicotine vaccine using nano-lipoplex as a delivery vehicle.

Hu Y, Zheng H, Huang W, Zhang C.

Hum Vaccin Immunother. 2014;10(1):64-72. doi: 10.4161/hv.26635. Epub 2013 Oct 7.

3.

Liposomal vaccine delivery systems.

Henriksen-Lacey M, Korsholm KS, Andersen P, Perrie Y, Christensen D.

Expert Opin Drug Deliv. 2011 Apr;8(4):505-19. doi: 10.1517/17425247.2011.558081. Epub 2011 Mar 18. Review.

PMID:
21413904
4.

High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants.

Chen X, Pravetoni M, Bhayana B, Pentel PR, Wu MX.

Vaccine. 2012 Dec 17;31(1):159-64. doi: 10.1016/j.vaccine.2012.10.069. Epub 2012 Oct 30.

5.

Cationic liposomes as vaccine adjuvants.

Christensen D, Korsholm KS, Andersen P, Agger EM.

Expert Rev Vaccines. 2011 Apr;10(4):513-21. doi: 10.1586/erv.11.17. Review.

PMID:
21506648
6.

Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum.

de Villiers SH, Cornish KE, Troska AJ, Pravetoni M, Pentel PR.

Vaccine. 2013 Dec 16;31(52):6185-93. doi: 10.1016/j.vaccine.2013.10.051. Epub 2013 Oct 29.

7.

Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.

Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW.

Int J Pharm. 2008 Dec 8;364(2):272-80. doi: 10.1016/j.ijpharm.2008.04.036. Epub 2008 Apr 30. Review.

PMID:
18555624
8.

Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection.

Mazumder S, Maji M, Ali N.

PLoS Negl Trop Dis. 2011 Dec;5(12):e1429. doi: 10.1371/journal.pntd.0001429. Epub 2011 Dec 20.

9.

Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates.

McCluskie MJ, Pryde DC, Gervais DP, Stead DR, Zhang N, Benoit M, Robertson K, Kim IJ, Tharmanathan T, Merson JR, Davis HL.

Int Immunopharmacol. 2013 May;16(1):50-6. doi: 10.1016/j.intimp.2013.03.021. Epub 2013 Apr 2.

PMID:
23562759
10.

Immunogenicity of individual vaccine components in a bivalent nicotine vaccine differ according to vaccine formulation and administration conditions.

Cornish KE, de Villiers SH, Pravetoni M, Pentel PR.

PLoS One. 2013 Dec 2;8(12):e82557. doi: 10.1371/journal.pone.0082557. eCollection 2013.

11.

PEGylated cationic liposomes robustly augment vaccine-induced immune responses: Role of lymphatic trafficking and biodistribution.

Zhuang Y, Ma Y, Wang C, Hai L, Yan C, Zhang Y, Liu F, Cai L.

J Control Release. 2012 Apr 10;159(1):135-42. doi: 10.1016/j.jconrel.2011.12.017. Epub 2011 Dec 29.

PMID:
22226776
12.

Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status.

Korsholm KS, Andersen PL, Christensen D.

Expert Rev Vaccines. 2012 May;11(5):561-77. doi: 10.1586/erv.12.22. Review.

PMID:
22827242
13.

New directions in nicotine vaccine design and use.

Pentel PR, LeSage MG.

Adv Pharmacol. 2014;69:553-80. doi: 10.1016/B978-0-12-420118-7.00014-7. Review.

14.

Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants.

Hussain MJ, Wilkinson A, Bramwell VW, Christensen D, Perrie Y.

J Pharm Pharmacol. 2014 Mar;66(3):358-66. doi: 10.1111/jphp.12173. Epub 2013 Nov 19.

PMID:
24251796
15.

Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice.

Pryde DC, Jones LH, Gervais DP, Stead DR, Blakemore DC, Selby MD, Brown AD, Coe JW, Badland M, Beal DM, Glen R, Wharton Y, Miller GJ, White P, Zhang N, Benoit M, Robertson K, Merson JR, Davis HL, McCluskie MJ.

PLoS One. 2013 Oct 1;8(10):e76557. doi: 10.1371/journal.pone.0076557. eCollection 2013.

16.

TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines.

Johnston D, Zaidi B, Bystryn JC.

Cancer Immunol Immunother. 2007 Aug;56(8):1133-41. Epub 2006 Dec 1.

PMID:
17139492
17.

Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Watson DS, Endsley AN, Huang L.

Vaccine. 2012 Mar 16;30(13):2256-72. doi: 10.1016/j.vaccine.2012.01.070. Epub 2012 Feb 2. Review. Erratum in: Vaccine. 2012 Aug 24;30(39):5799.

18.

Negatively Charged Carbon Nanohorn Supported Cationic Liposome Nanoparticles: A Novel Delivery Vehicle for Anti-Nicotine Vaccine.

Zheng H, Hu Y, Huang W, de Villiers S, Pentel P, Zhang J, Dorn H, Ehrich M, Zhang C.

J Biomed Nanotechnol. 2015 Dec;11(12):2197-210.

PMID:
26510313
19.

Probing the protective effects of a conformationally constrained nicotine vaccine.

Moreno AY, Azar MR, Koob GF, Janda KD.

Vaccine. 2012 Oct 19;30(47):6665-70. doi: 10.1016/j.vaccine.2012.08.064. Epub 2012 Sep 7.

PMID:
22963803
20.

Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine.

Johnston D, Bystryn JC.

Vaccine. 2006 Mar 10;24(11):1958-65. Epub 2005 Nov 8.

PMID:
16310898
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk